IL107896A - Method for the production of apoliprotein ai-m and an expression vector enabling said production - Google Patents
Method for the production of apoliprotein ai-m and an expression vector enabling said productionInfo
- Publication number
- IL107896A IL107896A IL10789693A IL10789693A IL107896A IL 107896 A IL107896 A IL 107896A IL 10789693 A IL10789693 A IL 10789693A IL 10789693 A IL10789693 A IL 10789693A IL 107896 A IL107896 A IL 107896A
- Authority
- IL
- Israel
- Prior art keywords
- apolipoprotein
- promoter
- apo
- production
- sequence coding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9203753A SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Expression system for producing apolipoprotein ai-m |
Publications (2)
Publication Number | Publication Date |
---|---|
IL107896A0 IL107896A0 (en) | 1994-04-12 |
IL107896A true IL107896A (en) | 2004-06-01 |
Family
ID=20388112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL10789693A IL107896A (en) | 1992-12-11 | 1993-12-06 | Method for the production of apoliprotein ai-m and an expression vector enabling said production |
Country Status (22)
Country | Link |
---|---|
US (1) | US5721114A (pl) |
EP (1) | EP0677109B1 (pl) |
JP (1) | JP3899121B2 (pl) |
AT (1) | ATE191930T1 (pl) |
AU (1) | AU5663794A (pl) |
CA (1) | CA2150928C (pl) |
CZ (1) | CZ290865B6 (pl) |
DE (1) | DE69328442T2 (pl) |
DK (1) | DK0677109T3 (pl) |
ES (1) | ES2146646T3 (pl) |
FI (1) | FI952847A (pl) |
GR (1) | GR3033966T3 (pl) |
HU (1) | HU220193B (pl) |
IL (1) | IL107896A (pl) |
MX (1) | MX9307855A (pl) |
NO (1) | NO319497B1 (pl) |
PL (1) | PL175955B1 (pl) |
PT (1) | PT677109E (pl) |
SE (1) | SE9203753D0 (pl) |
SK (1) | SK76695A3 (pl) |
WO (1) | WO1994013819A1 (pl) |
ZA (1) | ZA939266B (pl) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
DE69636907T2 (de) * | 1995-11-09 | 2007-11-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose |
SE9603068D0 (sv) * | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
SE9603304D0 (sv) * | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a compound |
SE9603303D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
US6306433B1 (en) | 1997-08-12 | 2001-10-23 | Pharmacia Ab | Method of preparing pharmaceutical compositions |
US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6046166A (en) | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
CN1297932A (zh) * | 1999-11-30 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸 |
US20020064820A1 (en) * | 2000-03-13 | 2002-05-30 | Jean-Michel Dayer | Apo-A-I regulation of T-cell signaling |
JP4344136B2 (ja) * | 2000-11-10 | 2009-10-14 | エフ・ホフマン−ラ・ロシュ・リミテッド | アポリポタンパク質類似体 |
US7217785B2 (en) * | 2001-05-09 | 2007-05-15 | The Regents Of The University Of California | Cysteine-containing peptides having antioxidant properties |
JP2005504085A (ja) * | 2001-09-28 | 2005-02-10 | エスペリオン セラピューティクス,インコーポレイテッド | 薬剤の局所投与による再狭窄の予防および治療 |
US20030162758A1 (en) * | 2001-12-07 | 2003-08-28 | Schwartz Daniel M. | Treatment for age-related macular degeneration (AMD) |
US20030229062A1 (en) * | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
US7470659B2 (en) * | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
US7223726B2 (en) * | 2002-01-14 | 2007-05-29 | The Regents Of The University Of California | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same |
US7691965B2 (en) * | 2002-05-08 | 2010-04-06 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
US20100204103A1 (en) * | 2002-05-08 | 2010-08-12 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
WO2003096983A2 (en) | 2002-05-17 | 2003-11-27 | Esperion Therapeutics, Inc. | Method of treating dyslipidemic disorders |
US20040038891A1 (en) * | 2002-05-17 | 2004-02-26 | Bisgaier Charles L. | Methods and compositions for the treatment of ischemic reperfusion |
HUE036646T2 (hu) | 2003-01-23 | 2018-07-30 | Esperion Therapeutics Inc | Hidroxilvegyületek és kompozícióik koleszterin szabályozására és kapcsolódó alkalmazásokra |
ATE486936T1 (de) * | 2003-03-05 | 2010-11-15 | Chemo Sero Therapeut Res Inst | Verfahren zur herstellung eines heterologen proteins in e. coli |
EP1732383A4 (en) * | 2004-04-06 | 2007-05-02 | Cedars Sinai Medical Center | PREVENTION AND TREATMENT OF VASCULAR DISEASES WITH VIRUS VECTORS ASSOCIATED WITH RECOMBINANT ADENOVIRUS CODING APOLIPOPROTEIN A-I AND APOLIPOPROTEIN A-I MILANO |
KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 a-ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
CN1320119C (zh) * | 2004-12-09 | 2007-06-06 | 复旦大学 | 人载脂蛋白ApoAⅠ在毕赤氏酵母胞内表达的方法 |
JP5113752B2 (ja) | 2005-08-22 | 2013-01-09 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | Lynキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤 |
JP2009505652A (ja) * | 2005-08-26 | 2009-02-12 | セレニス セラピューティクス ホールディング エスア | 乳酸菌においてアポリポタンパク質遺伝子生成物を生成するための組成物および方法 |
DE102006004871A1 (de) | 2006-02-02 | 2007-08-09 | Wacker Chemie Ag | Mikroorganismenstamm zur Produktion von rekombinanten Proteinen |
US20070254832A1 (en) * | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
MX2008015337A (es) | 2006-06-01 | 2009-11-26 | Inst Cardiologie Montreal | Metodo y compuesto para el tratamiento de estenosis valvular. |
DK1903115T3 (da) | 2006-09-22 | 2011-05-23 | Wacker Chemie Ag | Fremgangsmåde til fermentativ fremstilling af antistoffer |
DE102006044841A1 (de) | 2006-09-22 | 2008-04-03 | Wacker Chemie Ag | Signalpeptid zur Produktion von rekombinanten Proteinen |
DE102006050332A1 (de) | 2006-10-25 | 2008-04-30 | Wacker Chemie Ag | DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen |
AU2008210586B2 (en) * | 2007-01-31 | 2013-07-04 | Nutrition 21, Inc. | Use of chromium histidinate for treatment of cardiometabolic disorders |
CN101686686A (zh) * | 2007-02-20 | 2010-03-31 | 梅里奥尔医药I公司 | 鉴别Lyn激酶激活剂的方法 |
ES2579229T3 (es) | 2007-03-13 | 2016-08-08 | Jds Therapeutics, Llc | Procedimientos y composiciones para la liberación sostenida de cromo |
WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
EP2180894A4 (en) * | 2007-07-23 | 2012-08-29 | Melior Pharmaceuticals I Inc | METHOD OF ACTIVATING IRS-1 AND ACT |
EA201070517A1 (ru) * | 2007-10-23 | 2010-12-30 | Дзе Кливленд Клиник Фаундейшн | Устойчивый к окислителям аполипопротеин а-1 и пептиды-миметики |
US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
KR20220138415A (ko) | 2008-11-10 | 2022-10-12 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
CA3036963A1 (en) | 2009-01-29 | 2010-08-05 | Arbutus Biopharma Corporation | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
ES2620478T3 (es) | 2009-02-16 | 2017-06-28 | Cerenis Therapeutics Holding Sa | Miméticos de la apolipoproteína A-I |
JP6032724B2 (ja) | 2009-03-12 | 2016-11-30 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 脂質製剤組成物およびEg5遺伝子とVEGF遺伝子の発現を阻害する方法 |
KR102229618B1 (ko) | 2009-05-05 | 2021-03-18 | 알닐람 파마슈티칼스 인코포레이티드 | 지질 조성물 |
HRP20211619T1 (hr) | 2009-06-10 | 2022-02-04 | Arbutus Biopharma Corporation | Poboljšana formulacija lipida |
US9029338B2 (en) | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
DE102009053566B4 (de) | 2009-11-11 | 2014-08-14 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Mikroorganismen mit gesteigerter Sucrosemutaseaktivität |
EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
NZ600725A (en) | 2009-12-18 | 2015-08-28 | Univ British Colombia | Methods and compositions for delivery of nucleic acids |
WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
US20130137628A1 (en) | 2010-05-11 | 2013-05-30 | Esperion Therapeutics, Inc. | Dimeric Oxidation-Resistant Apolipoprotein A1 Variants |
WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
IL300109A (en) | 2010-06-03 | 2023-03-01 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the transfer of active substances |
US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US20130323269A1 (en) | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
BR112013004396A2 (pt) * | 2010-08-30 | 2016-05-17 | Hoffmann La Roche | alimentação alcalina |
CN103370054A (zh) | 2010-11-09 | 2013-10-23 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法 |
AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
CN103443123B (zh) | 2011-02-07 | 2020-05-29 | 塞勒尼斯医疗控股公司 | 脂蛋白复合物及其制备和用途 |
CN103702672B (zh) | 2011-03-01 | 2016-04-27 | Jds治疗有限公司 | 用于预防和治疗糖尿病、低血糖症及相关病症的胰岛素和铬组合物 |
US9701623B2 (en) | 2011-09-27 | 2017-07-11 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
JP6152387B2 (ja) | 2011-12-12 | 2017-06-21 | メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド | I型およびii型糖尿病の処置 |
WO2014011908A1 (en) | 2012-07-11 | 2014-01-16 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
MX2016014306A (es) | 2014-05-02 | 2017-06-12 | Cerenis Therapeutics Holding Sa | Marcadores para terapia con lipoproteinas de alta densidad (hdl). |
US11865121B2 (en) | 2016-02-11 | 2024-01-09 | Nutrition21, LLC | Chromium containing compositions for improving health and fitness |
US10426817B2 (en) * | 2017-01-24 | 2019-10-01 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics |
BR112019021140A2 (pt) | 2017-04-10 | 2020-05-19 | Univ Louisiana State | composição, método para reduzir os níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento, método de indução do bege de adipócitos ou prevenção da degeneração das células beta do pâncreas, e, ativador de lyn cinase e agonista de trpm8 para uso na redução dos níveis de glicose no sangue, ganho de peso ou níveis de depósito de gordura, ou tratamento. |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8625435D0 (en) * | 1986-10-23 | 1986-11-26 | Erba Farmitalia | Human apolipoprotein ai |
DE68917379T2 (de) * | 1988-05-31 | 1994-12-01 | Mitsubishi Chem Ind | Verfahren zur Herstellung von Proteinen, die ähnlich dem natürlich-menschlichen Apolipoprotein-E sind. |
DE3819463A1 (de) * | 1988-06-08 | 1989-12-14 | Behringwerke Ag | Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen |
US5223407A (en) * | 1988-08-31 | 1993-06-29 | Allelix Inc. | Excretion of heterologous proteins from e. coli |
IT1229996B (it) * | 1989-04-20 | 1991-09-20 | Cesare Sirtori | Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine. |
EP0497757B1 (en) * | 1989-10-31 | 1994-06-22 | Schering Corporation | E. coli secretory strains |
DE4009268A1 (de) * | 1990-03-22 | 1991-09-26 | Consortium Elektrochem Ind | Sekretion von hirudinderivaten |
SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
-
1992
- 1992-12-11 SE SE9203753A patent/SE9203753D0/xx unknown
-
1993
- 1993-12-06 IL IL10789693A patent/IL107896A/en not_active IP Right Cessation
- 1993-12-09 JP JP51405994A patent/JP3899121B2/ja not_active Expired - Fee Related
- 1993-12-09 PT PT94902173T patent/PT677109E/pt unknown
- 1993-12-09 US US08/448,606 patent/US5721114A/en not_active Expired - Fee Related
- 1993-12-09 CA CA002150928A patent/CA2150928C/en not_active Expired - Fee Related
- 1993-12-09 PL PL93309292A patent/PL175955B1/pl not_active IP Right Cessation
- 1993-12-09 DE DE69328442T patent/DE69328442T2/de not_active Expired - Fee Related
- 1993-12-09 CZ CZ19951487A patent/CZ290865B6/cs not_active IP Right Cessation
- 1993-12-09 AT AT94902173T patent/ATE191930T1/de not_active IP Right Cessation
- 1993-12-09 DK DK94902173T patent/DK0677109T3/da active
- 1993-12-09 ES ES94902173T patent/ES2146646T3/es not_active Expired - Lifetime
- 1993-12-09 SK SK766-95A patent/SK76695A3/sk unknown
- 1993-12-09 AU AU56637/94A patent/AU5663794A/en not_active Abandoned
- 1993-12-09 WO PCT/SE1993/001061 patent/WO1994013819A1/en active IP Right Grant
- 1993-12-09 EP EP94902173A patent/EP0677109B1/en not_active Expired - Lifetime
- 1993-12-09 HU HU9501680A patent/HU220193B/hu not_active IP Right Cessation
- 1993-12-10 ZA ZA939266A patent/ZA939266B/xx unknown
- 1993-12-10 MX MX9307855A patent/MX9307855A/es not_active IP Right Cessation
-
1995
- 1995-06-09 NO NO19952297A patent/NO319497B1/no unknown
- 1995-06-09 FI FI952847A patent/FI952847A/fi unknown
-
2000
- 2000-07-17 GR GR20000401651T patent/GR3033966T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
JPH08506723A (ja) | 1996-07-23 |
HUT71697A (en) | 1996-01-29 |
GR3033966T3 (en) | 2000-11-30 |
NO952297L (no) | 1995-06-09 |
ES2146646T3 (es) | 2000-08-16 |
HU9501680D0 (en) | 1995-08-28 |
NO952297D0 (no) | 1995-06-09 |
EP0677109B1 (en) | 2000-04-19 |
HU220193B (hu) | 2001-11-28 |
MX9307855A (es) | 1994-06-30 |
AU5663794A (en) | 1994-07-04 |
WO1994013819A1 (en) | 1994-06-23 |
CZ148795A3 (en) | 1996-01-17 |
PL309292A1 (en) | 1995-10-02 |
ATE191930T1 (de) | 2000-05-15 |
DE69328442T2 (de) | 2000-09-07 |
FI952847A0 (fi) | 1995-06-09 |
JP3899121B2 (ja) | 2007-03-28 |
PT677109E (pt) | 2000-07-31 |
US5721114A (en) | 1998-02-24 |
DK0677109T3 (da) | 2000-07-17 |
CA2150928A1 (en) | 1994-06-23 |
CZ290865B6 (cs) | 2002-11-13 |
PL175955B1 (pl) | 1999-03-31 |
CA2150928C (en) | 2005-02-08 |
FI952847A (fi) | 1995-06-09 |
DE69328442D1 (de) | 2000-05-25 |
ZA939266B (en) | 1994-08-08 |
SE9203753D0 (sv) | 1992-12-11 |
SK76695A3 (en) | 1996-02-07 |
EP0677109A1 (en) | 1995-10-18 |
NO319497B1 (no) | 2005-08-22 |
IL107896A0 (en) | 1994-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5721114A (en) | Expression system for producing apolipoprotein AI-M | |
KR970005928B1 (ko) | 프라세싱 부위에 인접한 음전하를 띤 아미노산을 함유하는 이스트 프라세싱 시스템 | |
US5004686A (en) | Process for producing human epidermal growth factor and analogs thereof | |
Amann et al. | Tightly regulated tac promoter vectors useful for the expression of unfused and fused proteins in Escherichia coli | |
KR100316347B1 (ko) | 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법 | |
US5357044A (en) | Cecropins fusion proteins | |
US5874406A (en) | Synthetic peptide analogs of lung surface protein SP-C | |
JP3730255B2 (ja) | イーストにおいて発現されたn末端に伸長した蛋白質 | |
US5962270A (en) | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs | |
US5206154A (en) | Method of producing cecropins by microbiological techniques | |
Chaudhary et al. | Role of domain II of Pseudomonas exotoxin in the secretion of proteins into the periplasm and medium by Escherichia coli. | |
CZ284204B6 (cs) | Zvyšování sekrece polypeptidů | |
JP2001008697A (ja) | E.コリでの非融合タンパク質の調製方法 | |
EP0946735A1 (en) | N-terminally extended proteins expressed in yeast | |
KR100659671B1 (ko) | 신규한 융합단백질로부터 재조합 인슐린을 제조하는 방법 | |
EP0868523B1 (en) | Vector for expression of n-terminally extended proteins in yeast cell | |
RU2144957C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА | |
AU643194B2 (en) | Recombinant fish hormone proteins | |
KR970000594B1 (ko) | deo 프로모터를 함유하는 형질발현 플라스미드 및 플라스미드를 함유하는 세균숙주 | |
EP0318580A4 (en) | Preparation of novel protein sweeteners | |
JP2003079379A (ja) | 成長ホルモンの高発現用dnaおよびその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |